Literature DB >> 25070989

Risk of vascular events in patients with polymyalgia rheumatica.

Adam T Hancock1, Christian D Mallen2, Sara Muller1, John Belcher1, Edward Roddy1, Toby Helliwell1, Samantha L Hider1.   

Abstract

BACKGROUND: Polymyalgia rheumatica is one of the most common inflammatory rheumatologic conditions in older adults. Other inflammatory rheumatologic disorders are associated with an excess risk of vascular disease. We investigated whether polymyalgia rheumatica is associated with an increased risk of vascular events.
METHODS: We used the General Practice Research Database to identify patients with a diagnosis of incident polymyalgia rheumatica between Jan. 1, 1987, and Dec. 31, 1999. Patients were matched by age, sex and practice with up to 5 patients without polymyalgia rheumatica. Patients were followed until their first vascular event (cardiovascular, cerebrovascular, peripheral vascular) or the end of available records (May 2011). All participants were free of vascular disease before the diagnosis of polymyalgia rheumatica (or matched date). We used Cox regression models to compare time to first vascular event in patients with and without polymyalgia rheumatica.
RESULTS: A total of 3249 patients with polymyalgia rheumatica and 12 735 patients without were included in the final sample. Over a median follow-up period of 7.8 (interquartile range 3.3-12.4) years, the rate of vascular events was higher among patients with polymyalgia rheumatica than among those without (36.1 v. 12.2 per 1000 person-years; adjusted hazard ratio 2.6, 95% confidence interval 2.4-2.9). The increased risk of a vascular event was similar for each vascular disease end point. The magnitude of risk was higher in early disease and in patients younger than 60 years at diagnosis.
INTERPRETATION: Patients with polymyalgia rheumatica have an increased risk of vascular events. This risk is greatest in the youngest age groups. As with other forms of inflammatory arthritis, patients with polymyalgia rheumatica should have their vascular risk factors identified and actively managed to reduce this excess risk.
© 2014 Canadian Medical Association or its licensors.

Entities:  

Mesh:

Year:  2014        PMID: 25070989      PMCID: PMC4162802          DOI: 10.1503/cmaj.140266

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  37 in total

Review 1.  Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Sylvain Mathieu; Laure Gossec; Maxime Dougados; Martin Soubrier
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

2.  Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome.

Authors:  Kevin Barraclough; William G Liddell; Jennifer du Toit; Christopher Foy; Bhaskar Dasgupta; Mike Thomas; William Hamilton
Journal:  Fam Pract       Date:  2008-08-07       Impact factor: 2.267

Review 3.  Polymyalgia rheumatica.

Authors:  Clement J Michet; Eric L Matteson
Journal:  BMJ       Date:  2008-04-05

4.  BSR and BHPR guidelines for the management of polymyalgia rheumatica.

Authors:  Bhaskar Dasgupta; Frances A Borg; Nada Hassan; Kevin Barraclough; Brian Bourke; Joan Fulcher; Jane Hollywood; Andrew Hutchings; Valerie Kyle; Jennifer Nott; Michael Power; Ash Samanta
Journal:  Rheumatology (Oxford)       Date:  2009-11-12       Impact factor: 7.580

Review 5.  Validity of diagnostic coding within the General Practice Research Database: a systematic review.

Authors:  Nada F Khan; Sian E Harrison; Peter W Rose
Journal:  Br J Gen Pract       Date:  2010-03       Impact factor: 5.386

6.  The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.

Authors:  Cynthia S Crowson; Eric L Matteson; Elena Myasoedova; Clement J Michet; Floranne C Ernste; Kenneth J Warrington; John M Davis; Gene G Hunder; Terry M Therneau; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2011-03

7.  Direct medical costs of polymyalgia rheumatica.

Authors:  Hilal Maradit Kremers; Megan S Reinalda; Cynthia S Crowson; Alan R Zinsmeister; Gene G Hunder; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2005-08-15

Review 8.  Chronic inflammatory diseases and cardiovascular risk: a systematic review.

Authors:  Idan Roifman; Paul L Beck; Todd J Anderson; Mark J Eisenberg; Jacques Genest
Journal:  Can J Cardiol       Date:  2011 Mar-Apr       Impact factor: 5.223

9.  Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica.

Authors:  Hilal Maradit Kremers; Megan S Reinalda; Cynthia S Crowson; John M Davis; Gene G Hunder; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2007-03-15

Review 10.  Cardiovascular involvement in psoriatic arthritis.

Authors:  F Atzeni; M Turiel; L Boccassini; S Sitia; L Tomasoni; M Battellino; A Marchesoni; V De Gennaro Colonna; P Sarzi-Puttini
Journal:  Reumatismo       Date:  2011-11-09
View more
  12 in total

1.  Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.

Authors:  Izzat Shbeeb; Divya Challah; Shafay Raheel; Cynthia S Crowson; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-22       Impact factor: 4.794

Review 2.  [S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations].

Authors:  F Buttgereit; T Brabant; H Dinges; I Hiemer; M Kaplani; U Kiltz; D Kyburz; A Reißhauer; M Schneider; C Weseloh; C Dejaco
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

Review 3.  Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies.

Authors:  Patompong Ungprasert; Matthew J Koster; Kenneth J Warrington; Eric L Matteson
Journal:  Rheumatol Int       Date:  2016-08-30       Impact factor: 2.631

Review 4.  The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy.

Authors:  Emma Harris; Ana Tiganescu; Sandy Tubeuf; Sarah Louise Mackie
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

5.  Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases.

Authors:  Mar Pujades-Rodriguez; Bram Duyx; Sara L Thomas; Dimitris Stogiannis; Liam Smeeth; Harry Hemingway
Journal:  Heart       Date:  2016-01-19       Impact factor: 5.994

Review 6.  Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies.

Authors:  Marie Holmqvist; Julia F Simard; Kjell Asplund; Elizabeth V Arkema
Journal:  RMD Open       Date:  2015-12-16

7.  Characterising those with incident polymyalgia rheumatica in primary care: results from the PMR Cohort Study.

Authors:  Sara Muller; Samantha L Hider; Toby Helliwell; Sarah Lawton; Kevin Barraclough; Bhaskar Dasgupta; Irena Zwierska; Christian D Mallen
Journal:  Arthritis Res Ther       Date:  2016-09-07       Impact factor: 5.156

8.  Incident acute pseudogout and prior bisphosphonate use: Matched case-control study in the UK-Clinical Practice Research Datalink.

Authors:  Edward Roddy; Sara Muller; Zoe Paskins; Samantha L Hider; Milisa Blagojevic-Bucknall; Christian D Mallen
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

9.  Challenges of diagnosing and managing polymyalgia rheumatica: a multi-methods study in UK general practice.

Authors:  Toby Helliwell; Sara Muller; Samantha L Hider; Irena Zwierska; Sarah Lawton; Jane Richardson; Christian Mallen
Journal:  Br J Gen Pract       Date:  2018-11       Impact factor: 5.386

10.  Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review.

Authors:  Sarah Louise Mackie; Gouri Koduri; Catherine L Hill; Richard J Wakefield; Andrew Hutchings; Clement Loy; Bhaskar Dasgupta; Jeremy C Wyatt
Journal:  RMD Open       Date:  2015-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.